<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Retrovirology - Latest articles</title>
		<link>http://www.retrovirology.com</link>
		<description>The latest articles from Retrovirology (ISSN 1742-4690) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.retrovirology.com/content/5/1/90"/>			    
            
				    <rdf:li rdf:resource="http://www.retrovirology.com/content/5/1/89"/>			    
            
				    <rdf:li rdf:resource="http://www.retrovirology.com/content/5/1/88"/>			    
            
				    <rdf:li rdf:resource="http://www.retrovirology.com/content/5/1/87"/>			    
            
				    <rdf:li rdf:resource="http://www.retrovirology.com/content/5/1/86"/>			    
            
				    <rdf:li rdf:resource="http://www.retrovirology.com/content/5/1/85"/>			    
            
				    <rdf:li rdf:resource="http://www.retrovirology.com/content/5/1/84"/>			    
            
				    <rdf:li rdf:resource="http://www.retrovirology.com/content/5/1/83"/>			    
            
				    <rdf:li rdf:resource="http://www.retrovirology.com/content/5/1/82"/>			    
            
				    <rdf:li rdf:resource="http://www.retrovirology.com/content/5/1/81"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.retrovirology.com/content/5/1/90">
            
            <title>Activation and detection of HTLV-I Tax-specific CTLs by Epitope expressing Single-Chain Trimers of MHC Class I in a rat model</title>
			<description>Background:
Human T cell leukemia virus type I (HTLV-I) causes adult T-cell leukemia (ATL) in infected individuals after a long incubation period. Immunological studies have suggested that insufficient host T cell response to HTLV-I is a potential risk factor for ATL. To understand the relationship between host T cell response and HTLV-I pathogenesis in a rat model system, we have developed an activation and detection system of HTLV-I Tax-specific cytotoxic T lymphocytes (CTLs) by Epitope expressing Single-Chain Trimers (SCTs) of MHC Class I. 
Results:
We have established expression vectors which encode SCTs of rat MHC-I (RT1.Al) with Tax180-188 peptide. Human cell lines transfected with the established expression vectors were able to induce IFN-gamma and TNF-alpha production by a Tax180-188-specific CTL line, 4O1/C8. We have further fused the C-terminus of SCTs to EGFP and established cells expressing SCT-EGFP fusion protein on the surface. By co-cultivating the cells with 4O1/C8, we have confirmed that the epitope-specific CTLs acquired SCT-EGFP fusion proteins and that these EGFP-possessed CTLs were detectable by flow cytometric analysis. 
Conclusions:
We have generated a SCT of rat MHC-I linked to Tax epitope peptide, which can be applicable for the induction of Tax-specific CTLs in rat model systems of HTLV-I infection. We have also established a detection system of Tax-specific CTLs by using cells expressing SCTs fused with EGFP. These systems will be useful tools in understanding the role of HTLV-I specific CTLs in HTLV-I pathogenesis.</description>
			<link>http://www.retrovirology.com/content/5/1/90</link>
			
			 	<dc:creator>Takashi Ohashi, Mika Nagai, Hiroyuki Okada, Ryo Takayanagi and Hisatoshi Shida</dc:creator>
			
			<dc:source>Retrovirology 2008, 5:90</dc:source>
			<dc:date>2008-10-08</dc:date>
			<dc:identifier>doi:10.1186/1742-4690-5-90</dc:identifier>
			
			
							
					<prism:publicationName>Retrovirology</prism:publicationName>
					
			
							
					<prism:issn>1742-4690</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>90</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-10-08</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.retrovirology.com/content/5/1/89">
            
            <title>The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors</title>
			<description>Background:
HIV-1 infects macrophages and microglia in the brain and can cause neurological disorders in infected patients. We and others have shown that brain-derived envelope glycoproteins (Env) have lower CD4 dependence and higher avidity for CD4 than those from peripheral isolates, and we have also observed increased fusogenicity and reduced sensitivity to the fusion inhibitor T-1249. Due to the genetic differences between brain and spleen env from one individual throughout gp120 and in gp41's heptad repeat 2 (HR2), we investigated the viral determinants for the phenotypic differences by performing functional studies with chimeric and mutant Env.
Results:
Chimeric Env showed that the V1/V2-C2-V3 region in brain's gp120 determines the low CD4 dependence and high avidity for CD4, as well as macrophage tropism and reduced sensitivity to the small molecule BMS-378806. Changes in brain gp41's HR2 region did not contribute to the increased fusogenicity or to the reduced sensitivity to T-1249, since a T-1249-based peptide containing residues found in brain's but not in spleen's HR2 had similar potency than T-1249 and interacted similarly with an immobilized heptad repeat 1-derived peptide in surface plasmon resonance analysis. However, the increased fusogenicity and reduced T-1249 sensitivity of brain and certain chimeric Env mostly correlated with the low CD4 dependence and high avidity for CD4 determined by brain's V1-V3 region. Remarkably, most but not all of these low CD4-dependent, macrophage tropic envelopes glycoproteins also had increased sensitivity to the novel allosteric entry inhibitor HNG-105. The gp120's C2 region asparagine 283 (N283) has been previously associated with macrophage tropism, brain infection, lower CD4 dependence and higher CD4 affinity. Therefore, we introduced the N283T mutation into an env clone from a brain-derived isolate and into a brain tissue-derived env clone, and the T283N change into a spleen-derived env from the same individual; however, we found that their phenotypes were not affected.
Conclusions:
We have identified that the V1-V3 region of a brain-derived envelope glycoprotein seems to play a crucial role in determining not only the low CD4 dependence and increased macrophage tropism, but also the augmented fusogenicity and reduced sensitivity to T-1249 and BMS-378806. By contrast, increased sensitivity to HNG-105 mostly correlated with low CD4 dependence and macrophage tropism but was not determined by the presence of the brain's V1-V3 region, confirming that viral determinants of phenotypic changes in brain-derived envelope glycoproteins are likely complex and context-dependent.</description>
			<link>http://www.retrovirology.com/content/5/1/89</link>
			
			 	<dc:creator>Fiorella Rossi, Bianca Querido, Manideepthi Nimmagadda, Simon Cocklin, Sonia Navas-Martin and Julio Martin-Garcia</dc:creator>
			
			<dc:source>Retrovirology 2008, 5:89</dc:source>
			<dc:date>2008-10-06</dc:date>
			<dc:identifier>doi:10.1186/1742-4690-5-89</dc:identifier>
			
			
							
					<prism:publicationName>Retrovirology</prism:publicationName>
					
			
							
					<prism:issn>1742-4690</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>89</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-10-06</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.retrovirology.com/content/5/1/88">
            
            <title>Sometimes the impact factor outshines the H index </title>
			<description>Journal impact factor (which reflects a particular journal's quality) and H index (which reflects the number and quality of an author's publications) are two measures of research quality. It has been argued that the H index outperforms the impact factor for evaluation purposes. Using articles first-authored or last-authored by board members of Retrovirology, we show here that the reverse is true when the future success of an article is to be predicted. The H index proved unsuitable for this specific task because, surprisingly, an article's odds of becoming a 'hit' appear independent of the pre-eminence of its author. We discuss implications for the peer-review process.</description>
			<link>http://www.retrovirology.com/content/5/1/88</link>
			
			 	<dc:creator>Johannes Honekopp and Janet Kleber</dc:creator>
			
			<dc:source>Retrovirology 2008, 5:88</dc:source>
			<dc:date>2008-10-06</dc:date>
			<dc:identifier>doi:10.1186/1742-4690-5-88</dc:identifier>
			
			
							
					<prism:publicationName>Retrovirology</prism:publicationName>
					
			
							
					<prism:issn>1742-4690</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>88</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-10-06</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.retrovirology.com/content/5/1/87">
            
            <title>Direct Vpr-Vpr Interaction in Cells monitored by two Photon Fluorescence Correlation Spectroscopy and Fluorescence Lifetime Imaging</title>
			<description>Background:
The human immunodeficiency virus type 1 (HIV-1) encodes several regulatory proteins, notably Vpr which influences the survival of the infected cells by causing a G2/M arrest and apoptosis. Such an important role of Vpr in HIV-1 disease progression has fuelled a large number of studies, from its 3D structure to the characterization of specific cellular partners. However, no direct imaging and quantification of Vpr-Vpr interaction in living cells has yet been reported. To address this issue, eGFP- and mCherry proteins were tagged by Vpr, expressed in HeLa cells and their interaction was studied by two photon fluorescence lifetime imaging microscopy and fluorescence correlation spectroscopy.
Results:
Results show that Vpr forms homo-oligomers at or close to the nuclear envelope. Moreover, Vpr dimers and trimers were found in the cytoplasm and in the nucleus. Point mutations in the three &#945; helices of Vpr drastically impaired Vpr oligomerization and localization at the nuclear envelope while point mutations outside the helical regions had no effect. Theoretical structures of Vpr mutants reveal that mutations within the &#945;-helices could perturb the leucine zipper like motifs. The &#916;Q44 mutation has the most drastic effect since it likely disrupts the second helix. Finally, all Vpr point mutants caused cell apoptosis suggesting that Vpr-mediated apoptosis functions independently from Vpr oligomerization.
Conclusion:
We report that Vpr oligomerization in HeLa cells relies on the hydrophobic core formed by the three &#945; helices. This oligomerization is required for Vpr localization at the nuclear envelope but not for Vpr-mediated apoptosis.</description>
			<link>http://www.retrovirology.com/content/5/1/87</link>
			
			 	<dc:creator>Jo&#235;lle V Fritz, Pascal Didier, Jean-Pierre Clamme, Emmanuel Schaub, Delphine Muriaux, Charlotte Cabanne, Nelly Morellet, Serge Bouaziz, Jean-Luc Darlix, Yves M&#233;ly and Hugues de Rocquigny</dc:creator>
			
			<dc:source>Retrovirology 2008, 5:87</dc:source>
			<dc:date>2008-09-22</dc:date>
			<dc:identifier>doi:10.1186/1742-4690-5-87</dc:identifier>
			
			
							
					<prism:publicationName>Retrovirology</prism:publicationName>
					
			
							
					<prism:issn>1742-4690</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>87</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-22</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.retrovirology.com/content/5/1/86">
            
            <title>Human T-cell leukemia virus type I infects human lung epithelial cells and induces gene expression of cytokines, chemokines and cell adhesion molecules</title>
			<description>Background:
Human T-cell leukemia virus type I (HTLV-I) is associated with pulmonary diseases, characterized by bronchoalveolar lymphocytosis, which correlates with HTLV-I proviral DNA in carriers. HTLV-I Tax seems to be involved in the development of such pulmonary diseases through the local production of inflammatory cytokines and chemokines in T cells. However, little is known about induction of these genes by HTLV-I infection in lung epithelial cells.
Results:
We tested infection of lung epithelial cells by HTLV-I by coculture studies in which A549 alveolar and NCI-H292 tracheal epithelial cell lines were cocultured with MT-2, an HTLV-I-infected T-cell line. Changes in the expression of several cellular genes were assessed by reverse transcription-polymerase chain reaction, enzyme-linked immunosorbent assay and flow cytometry. Coculture with MT-2 cells resulted in infection of lung epithelial cells as confirmed by detection of proviral DNA, HTLV-I Tax expression and HTLV-I p19 in the latter cells. Infection was associated with induction of mRNA expression of various cytokines, chemokines and cell adhesion molecule. NF-&#954;B and AP-1 were also activated in HTLV-I-infected lung epithelial cells. In vivo studies showed Tax protein in lung epithelial cells of mice bearing Tax and patients with HTLV-I-related pulmonary diseases.
Conclusion:
Our results suggest that HTLV-I infects lung epithelial cells, with subsequent production of cytokines, chemokines and cell adhesion molecules through induction of NF-&#954;B and AP-1. These changes can contribute to the clinical features of HTLV-I-related pulmonary diseases.</description>
			<link>http://www.retrovirology.com/content/5/1/86</link>
			
			 	<dc:creator>Hiromitsu Teruya, Mariko Tomita, Masachika Senba, Chie Ishikawa, Maki Tamayose, Akiko Miyazato, Satomi Yara, Yuetsu Tanaka, Yoichiro Iwakura, Jiro Fujita and Naoki Mori</dc:creator>
			
			<dc:source>Retrovirology 2008, 5:86</dc:source>
			<dc:date>2008-09-22</dc:date>
			<dc:identifier>doi:10.1186/1742-4690-5-86</dc:identifier>
			
			
							
					<prism:publicationName>Retrovirology</prism:publicationName>
					
			
							
					<prism:issn>1742-4690</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>86</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-22</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.retrovirology.com/content/5/1/85">
            
            <title>How to engage Cofilin</title>
			<description>In HIV-infected people, resting CD4+ T cells are the main reservoir of latent virus and the reason for the failure of drug therapy to cure HIV infection.  Still, we do not have a complete understanding of the factors regulating HIV replication in these cells.  A recent paper in Cell describes a new trick that the virus uses to infect resting T cells.  Interaction between the viral gp120 and cellular HIV co-receptor, CXCR4, during viral entry initiates signaling that activates cofilin, the main regulator of actin polymerization.  As a result of this activation, actin is depolymerized, thus destroying the natural barrier to HIV replication.  I discuss implications of this study for our understanding of HIV biology and development of novel anti-HIV therapeutic approaches.</description>
			<link>http://www.retrovirology.com/content/5/1/85</link>
			
			 	<dc:creator>Michael Bukrinsky</dc:creator>
			
			<dc:source>Retrovirology 2008, 5:85</dc:source>
			<dc:date>2008-09-22</dc:date>
			<dc:identifier>doi:10.1186/1742-4690-5-85</dc:identifier>
			
			
							
					<prism:publicationName>Retrovirology</prism:publicationName>
					
			
							
					<prism:issn>1742-4690</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>85</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-22</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.retrovirology.com/content/5/1/84">
            
            <title>HIV-1 Nef: at the crossroads</title>
			<description>The development of anti-virals has blunted the AIDS epidemic in the Western world but globally the epidemic has not been curtailed. Standard vaccines have not worked, and attenuated vaccines are not being developed because of safety concerns. Interest in attenuated vaccines has centered on isolated cases of patients infected with HIV-1 containing a deleted nef gene. Nef is a multifunctional accessory protein that is necessary for full HIV-1 virulence. Unfortunately, some patients infected with the nef-deleted virus eventually lose their CD4+ T cells to levels indicating progression to AIDS.This renders the possibility of an attenuated HIV-1 based solely on a deleted nef remote. In this review we discuss the knowledge gained both from the study of these patients and from in vitro investigations of Nef function to assess the possibility of developing new anti-HIV-1 drugs based on Nef. Specifically, we consider CD4 downregulation, major histocompatibility complex I downregulation, Pak2 activation, and enhancement of virion infectivity. We also consider the recent proposal that simian immunodeficiency viruses are non-pathogenic in their hosts because they have Nefs that downregulate CD3, but HIV-1 is pathogenic because its Nef fails to downregulate CD3. The possibility of incorporating the CD3 downregulation function into HIV-1 Nef as a therapeutic option is also considered. Finally, we conclude that inhibiting the CD4 downregulation function is the most promising Nef-targeted approach for developing a new anti-viral as a contribution to combating AIDS.</description>
			<link>http://www.retrovirology.com/content/5/1/84</link>
			
			 	<dc:creator>John L Foster and J Victor Garcia</dc:creator>
			
			<dc:source>Retrovirology 2008, 5:84</dc:source>
			<dc:date>2008-09-22</dc:date>
			<dc:identifier>doi:10.1186/1742-4690-5-84</dc:identifier>
			
			
							
					<prism:publicationName>Retrovirology</prism:publicationName>
					
			
							
					<prism:issn>1742-4690</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>84</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-22</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.retrovirology.com/content/5/1/83">
            
            <title>Homonuclear 1H NMR and circular dichroism study of the HIV-1 Tat Eli variant</title>
			<description>Background:
The HIV-1 Tat protein is a promising target to develop AIDS therapies, particularly vaccines, due to its extracellular role that protects HIV-1-infected cells from the immune system. Tat exists in two different lengths, 86 or 87 residues and 99 or 101 residues, with the long form being predominant in clinical isolates. We report here a structural study of the 99 residue Tat Eli variant using 2D liquid-state NMR, molecular modeling and circular dichroism.
Results:
Tat Eli was obtained from solid-phase peptide synthesis and the purified protein was proven biologically active in a trans-activation assay. Circular dichroism spectra at different temperatures up to 70&#176;C showed that Tat Eli is not a random coil at 20&#176;C. Homonuclear 1H NMR spectra allowed us to identify 1639 NMR distance constraints out of which 264 were interresidual. Molecular modeling satisfying at least 1474 NMR constraints revealed the same folding for different model structures. The Tat Eli model has a core region composed of a part of the N-terminus including the highly conserved Trp 11. The extra residues in the Tat Eli C-terminus protrude from a groove between the basic region and the cysteine-rich region and are well exposed to the solvent.
Conclusion:
We show that active Tat variants share a similar folding pattern whatever their size, but mutations induce local structural changes.</description>
			<link>http://www.retrovirology.com/content/5/1/83</link>
			
			 	<dc:creator>Jennifer D Watkins, Grant R Campbell, Hubert Halimi and Erwann P Loret</dc:creator>
			
			<dc:source>Retrovirology 2008, 5:83</dc:source>
			<dc:date>2008-09-22</dc:date>
			<dc:identifier>doi:10.1186/1742-4690-5-83</dc:identifier>
			
			
							
					<prism:publicationName>Retrovirology</prism:publicationName>
					
			
							
					<prism:issn>1742-4690</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>83</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-22</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.retrovirology.com/content/5/1/82">
            
            <title>beta-estradiol attenuates the anti-HIV-1 efficacy of Stavudine (D4T) in primary PBL</title>
			<description>Background:
Female hormones are known to play an important role in predisposition for many infectious diseases. Recent work suggests there are gender effects in HIV/AIDS progression. Here we ask whether the sex steroid hormone &#946;-estradiol affects the replication of HIV-1 or the efficacy of a common anti-retroviral drug, Stavudine (D4T).
Results:
Human PBL were infected with HIV-1 in the presence or absence of combinations of sex steroid hormones and the anti-retroviral drug, D4T. After seven days in culture, viral supernatants were assayed for HIV-1 p24 protein. &#946;-estradiol resulted in a modest inhibition of HIV-1 replication of ~26%. However, 2 nM &#946;-estradiol increased the amount of HIV-1 replication in the presence of 50 nM D4T from a baseline of 33% (+/- SE = 5.4) to 74% (+/- SE = 5.4) of control virus levels in the absence of drug. Both results were statistically highly significant (p &lt; 0.001). &#946;-estradiol did not increase the replication of a D4T-resistant strain of HIV in the presence of D4T. The effects were unlikely to be due to general cell inhibition or toxicity because these concentrations of drug and hormone cause no cytotoxicity in PBL as measured by trypan blue exclusion.
Conclusion:
&#946;-estradiol inhibited both HIV-1 replication in primary human PBL and the antiretroviral efficacy of D4T in PBL cultures. To optimize antiretroviral drug therapy, it may be necessary to monitor patient hormonal status.</description>
			<link>http://www.retrovirology.com/content/5/1/82</link>
			
			 	<dc:creator>Mingjie Zhang, Qingsheng Huang, Yong Huang, Owen Wood, Weishi Yuan, Caren Chancey, Sylvester Daniel, Maria Rios, Indira Hewlett, Kathleen A Clouse and Andrew I Dayton</dc:creator>
			
			<dc:source>Retrovirology 2008, 5:82</dc:source>
			<dc:date>2008-09-22</dc:date>
			<dc:identifier>doi:10.1186/1742-4690-5-82</dc:identifier>
			
			
							
					<prism:publicationName>Retrovirology</prism:publicationName>
					
			
							
					<prism:issn>1742-4690</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>82</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-22</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.retrovirology.com/content/5/1/81">
            
            <title>ESF-EMBO Symposium: Antiviral Applications of RNA Interference</title>
			<description>The first ESF-EMBO symposium on applications of antiviral RNA interference (RNAi) was held in the spring of 2008 in Sant Feliu de Guixols at the Costa Brava in Spain. Some 60 participants from the field of RNAi and virology came together to present their latest findings on RNAi-virus interactions, as well as the progress in the development of RNAi-based antiviral therapeutics. One of the big topics concerned the role of RNAi in natural antiviral defence mechanisms in mammals. In addition, new solutions to improve the efficacy and safety of RNAi-based antiviral drugs were presented. The combined expertise of researchers studying RNAi in plants, insects and mammalian systems greatly stimulated the overall discussion. The meeting was funded by the European Science Foundation (ESF) in partnership with the European Molecular Biology Organisation (EMBO).</description>
			<link>http://www.retrovirology.com/content/5/1/81</link>
			
			 	<dc:creator>Olivier ter Brake, Joost Haasnoot, Jens Kurreck and Ben Berkhout</dc:creator>
			
			<dc:source>Retrovirology 2008, 5:81</dc:source>
			<dc:date>2008-09-18</dc:date>
			<dc:identifier>doi:10.1186/1742-4690-5-81</dc:identifier>
			
			
							
					<prism:publicationName>Retrovirology</prism:publicationName>
					
			
							
					<prism:issn>1742-4690</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>81</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-18</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
